Tryptamine Therapeutics (AU:TYP) has released an update.
Jason Carroll, a director of Tryptamine Therapeutics Limited, has increased his direct interest in the company by acquiring 952,748 ordinary fully paid shares at $0.022 each, totaling $20,960.46. This transaction, reported under the listing rule 3.19A.2, brings Carroll’s total holding to 34,452,748 ordinary shares, with no disposals noted and all within the compliance of trading regulations.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
